Literature DB >> 15494029

Regulation of cellular processes by PPARgamma ligands in neuroblastoma cells is modulated by the level of retinoblastoma protein expression.

V C Emmans1, H A Rodway, A N Hunt, K A Lillycrop.   

Abstract

Neuroblastoma is a childhood cancer, which spontaneously regresses. This has led to a search for agents that mimic this process. We show that both natural and synthetic ligands of PPARgamma (peroxisome-proliferator-activated receptor gamma) inhibit the growth of neuroblastoma cells in vitro. The degree of PPAR activation was attenuated however in the presence of the retinoblastoma protein. Addition of trichostatin A, a histone deacetylase inhibitor, abolished retinoblastoma protein repression of PPAR activity. Moreover, enhanced growth inhibition was observed when neuroblastoma cells were treated with a PPARgamma ligand and a histone deacetylase inhibitor, suggesting a combination therapy to treat neuroblastoma might prove more effective than using either agent alone.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15494029     DOI: 10.1042/BST0320840

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  8 in total

1.  PPARs in Human Neuroepithelial Tumors: PPAR Ligands as Anticancer Therapies for the Most Common Human Neuroepithelial Tumors.

Authors:  Elisabetta Benedetti; Renato Galzio; Barbara D'Angelo; Maria Paola Cerù; Annamaria Cimini
Journal:  PPAR Res       Date:  2010-03-17       Impact factor: 4.964

2.  Peroxisome Proliferator-Activated Receptors (PPARs) as Potential Inducers of Antineoplastic Effects in CNS Tumors.

Authors:  Lars Tatenhorst; Eric Hahnen; Michael T Heneka
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

Review 3.  PPAR Gamma in Neuroblastoma: The Translational Perspectives of Hypoglycemic Drugs.

Authors:  Serena Vella; Pier Giulio Conaldi; Tullio Florio; Aldo Pagano
Journal:  PPAR Res       Date:  2016-10-05       Impact factor: 4.964

4.  Induction of Apoptosis and Autophagy in Breast Cancer Cells by a Novel HDAC8 Inhibitor.

Authors:  Chang-Fang Chiu; Hsien-Kuo Chin; Wei-Jan Huang; Li-Yuan Bai; Hao-Yu Huang; Jing-Ru Weng
Journal:  Biomolecules       Date:  2019-12-04

5.  In vivo effects of rosiglitazone in a human neuroblastoma xenograft.

Authors:  I Cellai; G Petrangolini; M Tortoreto; G Pratesi; P Luciani; C Deledda; S Benvenuti; C Ricordati; S Gelmini; E Ceni; A Galli; M Balzi; P Faraoni; M Serio; A Peri
Journal:  Br J Cancer       Date:  2010-01-12       Impact factor: 7.640

6.  A novel mechanism of PPAR gamma induction via EGFR signalling constitutes rational for combination therapy in bladder cancer.

Authors:  Jose Joao Mansure; Roland Nassim; Simone Chevalier; Konrad Szymanski; Joice Rocha; Saad Aldousari; Wassim Kassouf
Journal:  PLoS One       Date:  2013-02-08       Impact factor: 3.240

7.  Synergistic Effects of PPARgamma Ligands and Retinoids in Cancer Treatment.

Authors:  Masahito Shimizu; Hisataka Moriwaki
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

8.  PPARgamma in Neuroblastoma.

Authors:  Alessandro Peri; Ilaria Cellai; Susanna Benvenuti; Paola Luciani; Silvana Baglioni; Mario Serio
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.